Filtyp
Don't miss the latest episode of MultiPark's podcast Meet our scientists. MultiPark's newest research group leader, Henrik Ahlenius, shares his expertise about stem cells in aging and neurodegenerative diseases. In this episode, Henrik explains the fascinating interplay between aging, neurodegenerative diseases and stem cells - critical areas of study that Henrik Ahlenius has passionately pursued
This week marked the kickoff of MultiPark's Advanced Neuroscience Course. In this exclusive program, students from around the world unite to explore neuroscience and the complexities of neurodegenerative diseases. During the Advanced Neuroscience Course, students gain insights from leading researchers and get hands-on lab experience, working closely with labs that match their interests. The course
https://www.multipark.lu.se/article/advanced-neuroscience-course-future-neuroscientists - 2026-10-15
A study at Lund University reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta — a hallmark of Alzheimer’s disease. The findings suggest that vascular dysfunction could be an early driver in neurodegenerative disorders rather than being caused by neuronal damage. The study is published in Acta Neuropathologica. An increased risk o
https://www.multipark.lu.se/article/cracking-alzheimers-code-how-brain-trauma-triggers-disease - 2026-10-15
This year, MultiPark has the pleasure of welcoming two new research groups. The Mackenzie Lab aims to decode the neurobiological underpinnings of emotion through experimental studies in animal models. Jacob Vogel’s team uses AI to analyze clinical data for improved understanding as well as patient-tailored diagnosis and care of neurodegenerative disease patients. Say hello to Åsa Mackenzie and Jac
https://www.multipark.lu.se/article/multipark-grows-new-research-groups - 2026-10-15
What role does an inflammatory protein have in disease development? Which neuronal circuits cause different symptoms? How may diabetes affect Parkinson’s disease? Can motor signs be identifies early in individuals at risk for the disease? And how should patients in very advanced disease stages be treated to maintain their quality of life? These questions may soon have answers thanks to several ong
https://www.multipark.lu.se/article/molecule-patient-six-promising-projects-advance-parkinsons-research - 2026-10-15
Researchers at Lund University and Washington University have identified a blood marker that reflects the amount of Alzheimer’s pathology in the brain. This discovery may play a key role in determining who is most likely to benefit from the new Alzheimer’s drugs. In brief:A newly discovered blood marker, MTBR-tau243, can reveal how much Alzheimer’s disease pathology is present in the brain. The hi
https://www.multipark.lu.se/article/new-reliable-blood-marker-reveals-extent-alzheimers-pathology-brain - 2026-10-15
A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led by Lund University in Sweden. “This is a major step in bringing simple blood tests for Alzheimer’s disease into the healthcare system globally,” say the researchers behind the study. In brief:The blood-based marker (P-tau217) may start to change several years before the onset of Al
https://www.multipark.lu.se/article/more-opportunities-test-alzheimers-using-new-analytical-method - 2026-10-15
Meet our scientist Gesine Paul-Visse to learn what happens at the interface where the brain and the body meet: the blood-brain barrier. Here, a very specialized cell, the pericyte, protects the brain and responds strongly to disease. Gesine Paul-Visse leads Translational Neurology, one of MultiPark’s research groups. As both a neurologist and a researcher, she has focused on neurodegeneration for
https://www.multipark.lu.se/article/meet-our-scientists-podcast-gesine-paul-visse-about-brains-frontline - 2026-10-15
Researchers at MultiPark have uncovered in mice how the protein TDP-43, known for its role in several neurodegenerative diseases, disrupts the hypothalamus, the brain’s key center for metabolic control. Their study sheds new light on the role of TDP-43 in metabolic and psychiatric symptoms shared across frontotemporal dementia, Huntington’s disease, and ALS – findings that could support the develo
An experimental study from Lund University reveals for the first time that different Parkinson’s medications affect brain activity in distinct ways. This could explain why some patients develop impulsive and compulsive behaviors as a result of their treatment. The findings have been published in NPJ Parkinson’s Disease. Upon receiving treatment for their motor symptoms, many patients with Parkinso
https://www.multipark.lu.se/article/brain-activation-pattern-behind-impulsivity-parkinsons-treatment-discovered - 2026-10-15
Meet our scientist, Dr. Niklas Mattsson-Carlgren! He explains why studying biomarkers is essential to advancing Alzheimer’s research. Niklas Mattsson-Carlgren is part of the Clinical Memory Research group, a leading centre in the development and evaluation of novel biomarkers for Alzheimer’s disease. In this podcast episode, he discusses why biomarker research is key not only to detecting but also
With over 15 research groups dedicated to Alzheimer’s disease research, MultiPark’s goal is to understand the origins of the disease, develop early diagnostics, and improve treatments. The multidisciplinary approach sheds light on the disease from several angles, bridging basic research with clinical investigations. Here are five projects. September is World Alzheimer’s Month. Globally, around 40
For decades, large stretches of human DNA were dismissed as ‘junk’ and considered to serve no real purpose. In a new study in Cell Genomics, researchers at Lund University in Sweden show that the repetitive part of the human genome plays an active role during early brain development and may also be relevant for understanding brain diseases. DNA carries the complete set of instructions an organism
https://www.multipark.lu.se/article/why-repetitive-dna-matters-human-brain-evolution-and-disease - 2026-10-15
New biomarkers can make Alzheimer’s disease easier to detect and diagnoses more accurate, which may be crucial as disease-modifying treatments are available. And the diagnostic toolbox could expand even further, predicts one of MultiPark’s newest research group leaders, who is working on an AI model designed to detect several different conditions linked to dementia from a single blood test. But Mu
Visual dysfunction is increasingly recognized as a feature of Alzheimer's disease. Yet the molecular basis of retinal changes had remained poorly defined, and no previous study has compared retinal and brain proteomes from the same individuals. Now, a study from MultiPark has mapped the proteins that are altered in the disease. The discoveries were recently published in Acta Neuropathologica. In a
https://www.multipark.lu.se/article/retina-future-window-alzheimers-disease - 2026-10-15
One of MultiPark’s research groups led by Professor Johan Jakobsson has uncovered a previously unknown link between inflammatory responses and the activation of repetitive DNA elements in affected brain regions from Parkinson’s disease patients. Their findings reveal underexplored disease processes and raise hopes of identifying future therapeutic targets. Transposable elements, sometimes called “
This article is over 5 years old, and the information may therefore be outdated. How do you stop Alzheimer’s disease without a simple way to diagnose it? It’s a real chicken and egg problem, as I wrote last year on TGN. Discovering a treatment for Alzheimer’s requires lots of clinical trials for new drugs—but it’s difficult to enroll participants without a way to identify people who have the disea
https://www.multipark.lu.se/article/unexpected-way-we-might-one-day-diagnose-alzheimers - 2026-10-15
Alzheimer’s researcher Sebastian Palmqvist has been awarded USD 19.4 million (SEK 190 million) from the US National Institutes of Health (NIH), through its National Institute on Aging (NIA). The funds are to be used to develop a clinical test based on the biomarker MTBR-tau243. The goal is to develop an FDA-approved blood test within five years that will benefit patients. “It’s a great pleasure to
https://www.multipark.lu.se/article/sek-190-million-research-and-development-new-diagnostic-test-alzheimers-disease - 2026-10-15
Last week, MultiPark participated at Skånska Demensdagen to share knowledge about current research and meet people working with dementia across different parts of society. Skånska Demensdagen brought together professionals from municipal and regional health and elderly care, among others. Participants also included managers, politicians and other decision-makers in the field. The event was moderat
https://www.multipark.lu.se/article/multipark-met-dementia-care-professionals-skanska-demensdagen - 2026-10-15
Both normal aging and Alzheimer’s change how different brain regions communicate with each other. But a new study from Lund University reveals that these alterations follow distinct patterns where shifts linked to disease are distinguishable from normal aging. And the alterations seen in Alzheimer’s patients appear early, even before cognitive symptoms emerge. The discoveries are published in Natu
https://www.multipark.lu.se/article/alzheimers-disease-and-aging-reshape-brain-communication-different-ways - 2026-10-15
